Welcome to our dedicated page for Ethos Technologies SEC filings (Ticker: LIFE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings associated with the LIFE ticker symbol document the regulatory history of aTyr Pharma, Inc. when its common stock traded under that symbol on the Nasdaq Capital Market. These filings include periodic reports and current reports that describe financial results, clinical progress, and other material events relevant to the company’s development as a clinical stage biotechnology enterprise focused on tRNA synthetase biology.
Among the filings, users may find Form 8-K and Form 8-K/A reports that aTyr has used to furnish quarterly financial results and clarify administrative matters. For example, an 8-K dated August 7, 2025 reports the issuance of a press release announcing financial results for the quarter ended June 30, 2025, while an 8-K/A filed the same day explains that the original submission header coding on EDGAR was corrected from an impairment item to the appropriate results-of-operations item. These documents illustrate how the company communicates financial performance and ensures accurate regulatory categorization of its disclosures.
In addition to current reports, the broader SEC record for aTyr under the LIFE symbol includes annual and quarterly reports that typically provide detailed discussions of its clinical programs, including the EFZO-FIT™ and EFZO-CONNECT™ studies of efzofitimod in interstitial lung disease, as well as descriptions of its tRNA synthetase-based discovery platform and associated risks. While those specific forms are not reproduced here, they can be accessed through the SEC’s EDGAR system under the company’s name and CIK.
On this page, Stock Titan presents aTyr’s SEC filings historically linked to the LIFE ticker with real-time updates from EDGAR and AI-powered summaries that explain the key points of each document in plain language. Users can quickly see what a particular 8-K, 10-Q, or 10-K addresses, such as financial condition, clinical trial developments, or corporate actions, without reading every page. The platform also surfaces insider transaction reports on Form 4, where available, to help users track equity transactions by directors and officers.
Because aTyr changed its Nasdaq ticker from LIFE to ATYR effective June 5, 2024, newer filings appear under the ATYR symbol even though they relate to the same registrant. Researchers examining the LIFE filings page gain historical context on the company’s earlier reporting under that symbol, while those seeking the most recent information should also review filings associated with ATYR. Together, these records provide a continuous view of aTyr Pharma’s regulatory disclosures as it advances efzofitimod and other programs based on its tRNA synthetase platform.